F S&P 500
5,544.50 +7.50 (+0.14%) F Dow Jones
39,532.00 +6.00 (+0.02%) F Nasdaq
20,016.00 +43.75 (+0.22%) E-mini Russell 2000 Index Futur
2,044.90 0.00 (0.00%) Petróleo
81.37 +0.54 (+0.67%) Oro
2,327.60 -3.20 (-0.14%)
Poxel S.A. (PXXLF)
Poxel S.A.
Immeuble Le Sunway
259-261 Avenue Jean JaurEs
Lyon 69007
France
33 1 44 71 94 94
https://www.poxelpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 15
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D. | Co-Founder, CEO & Director | 442.86k | N/D | N/D |
| Dr. Sébastien Bolze Ph.D., Pharm D Ph.D., Pharm.D. | Co-Founder, COO and Executive VP of Project Management, Non Clinical & Manufacturing Operations | N/D | N/D | N/D |
| Dr. Pascale Fouqueray-Grellier M.D., Ph.D. | Co-Founder and Executive VP of Clinical Development & Regulatory Affairs | N/D | N/D | N/D |
| Dr. Sophie Hallakou-Bozec Ph.D. | Co-Founder and Executive VP of R&D Pharmacology & Scientific Communication | N/D | N/D | N/D |
| Arthur Rouille | Investor Relations Officer | N/D | N/D | N/D |
| Mr. Quentin Durand | Executive VP, Chief Legal Officer & Head of Corporate Social Responsibility | N/D | N/D | N/D |
| Ms. Sylvie Bertrand | Vice President of Human Resources | N/D | N/D | N/D |
Descripción
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Gestión corporativa
La calificación ISS Governance QuickScore de Poxel S.A. a partir del 1 de junio de 2024 es 10. Las puntuaciones principales son Auditoría: 5; Junta: 9; Derechos del accionista: 4; Compensación: 10.
